Drug Profile
Research programme: autoimmune disease therapies - Resolve Therapeutics
Alternative Names: RSLV-125Latest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator Washington University
- Developer Resolve Therapeutics
- Class Anti-inflammatories; Biological proteins; Recombinant fusion proteins; Vascular disorder therapies
- Mechanism of Action Interferon alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Vasculitis
- No development reported Systemic lupus erythematosus
Most Recent Events
- 19 Jul 2023 Preclinical trials in Vasculitis in USA (Parenteral) (before July 2023) (Resolve Therapeutics Pipeline, July 2023)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA (Parenteral)
- 17 Mar 2014 RSVL 132 has entered clinical development for for Systemic lupus erythematosus in USA